Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading AIM ImmunoTech Inc chart...

About the Company

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as

CEO

Thomas Equels

Exchange

NYSE MKT LLC

Website

https://aimimmuno.com/

$0M

Total Revenue

23

Employees

$16M

Market Capitalization

-1.09

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AIM News

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

3d ago, source: Business Insider

OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM ...

AIM ImmunoTech Announces Launch of CEO Corner Platform

11d ago, source:

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progressProvides ...

Aimia Inc. PFD-1 declares CAD 0.3001 dividend

on MSN ago, source:

Aimia Inc. PFD-1 (AIM.PR.A:CA) declares CAD 0.3001/share quarterly dividend, in line with previous. Payable March 28; for shareholders of record March 21; ex-div March 20. See AIM.PR.A:CA Dividend ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...